Ilumina buys consulting firm

|By:, SA News Editor

Ilumina (NASDAQ:ILMN) acquires Myraqa, a regulatory and quality consulting form specializing in in vitro diagnostics, especially companion diagnostics. Myraqa's expertise is regulatory strategy and application support, including PMAs, pre-submissions, IDEs, 510(k)s and EU technical files. The acquisition beefs up Ilumina's in-house regulatory capabilities.

Myraqa CEO Mya Thomae will report to Ilumina CMO Rick Klausner, M.D.